$AMRN the failure of Strengh puzzles me. From a pure TG lowering standpoint, I think it would have hit most markers. So obviously it is the outcomes part that failed. Just shows the effect of DHA. This just pushes acst and mtnb further behind because only an outcomes study would be used by the FDA. Now they are both 5-6 years behind.